Inorgen’s participative vision: align research, patients, sponsors and professional community on the same goal.
ACADEMIC CENTERS, R&D INSTITUTIONS
Source lead candidates to enable drug development.
PATIENT ORGANIZATIONS and FOUNDATIONS
Identify specific needs and eventual assets that fit with an early stage development model.
SCIENTISTS and CLINICIANS
Decisions to continue or stop the course of action. Enable a risk mitigation development program.
DRUG DEVELOPMENT PROFESSIONALS
Accelerate the preparation of drug candidates partnering with experts in science, IP, regulatory, medical affairs, clinical research.
VENTURE CAPITAL / CORPORATE VENTURE
Highlight development and regulatory requirements to attract capital into a new initiative. Operate with a milestone-driven, capital efficient approach.
BIOPHARMA
Add opportunities to increase the pipeline in selected therapeutic areas achieving operational flexibility between internal and external resources.
Project requirements: premises for incubation.
MUST HAVE
∙ First or Best in Class
∙ Preclinical proof of concept
NICE TO HAVE
∙ Scientific publication
∙ Patent(s) and patentability study
Advisors and Professionals: liaising for project and company development.
Inorgen welcomes interactions with experienced individuals in the following areas: